Compare LGIH & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | NTLA |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2013 | 2016 |
| Metric | LGIH | NTLA |
|---|---|---|
| Price | $58.16 | $12.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 23 |
| Target Price | ★ $75.90 | $20.02 |
| AVG Volume (30 Days) | 295.5K | ★ 3.4M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $1,705,504,000.00 | $67,671,000.00 |
| Revenue This Year | $2.32 | N/A |
| Revenue Next Year | $17.94 | $62.75 |
| P/E Ratio | $46.53 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $33.55 | $7.95 |
| 52 Week High | $69.42 | $28.24 |
| Indicator | LGIH | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 51.07 |
| Support Level | $55.45 | $11.55 |
| Resistance Level | $62.97 | $15.52 |
| Average True Range (ATR) | 2.22 | 0.60 |
| MACD | -0.10 | 0.23 |
| Stochastic Oscillator | 46.38 | 63.84 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.